Comparison of the acute effects of a selective endothelin ET(A) and a mixed ET(A)/ET(B) receptor antagonist in heart failure

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 617-624

  Ohnishi, Masato ^a   Wada, Atsuyuki ^a   Tsutamoto, Takayoshi ^a   Fukai, Daisuke ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Antagonists; Dog; Endothelin; Heart failure; Neurohumoral factors

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NORADRENALIN; RES 701 1; TAK 044;

ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; DRUG SELECTIVITY; FEMALE; HEART OUTPUT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NATRIURESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ALDOSTERONE; ANALYSIS OF VARIANCE; ANIMALS; ATRIAL NATRIURETIC FACTOR; AZEPINES; CARDIAC PACING, ARTIFICIAL; DOGS; ENDOTHELIN-1; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; INDOLES; KIDNEY; MALE; PEPTIDES, CYCLIC; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; RENAL PLASMA FLOW; SODIUM;

EID: 0032167644     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00205-3     Document Type: Article

References (34)

1. Yanagisawa M., Kurihara H., Kimura S.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;441-445.
2. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348:1990;730-732.
3. DeNucci G., Thomas R., D'Orleans-Juste P.et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 85:1988;9797-9800.
4. B receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 107:1992;858-860.
5. Goetz K.L., Wang B.C., Madwed J.B., Zhu J.L., Leadley R.J. Jr. Cardiovascular, renal and endocrine response to intravenous endothelin in conscious dogs. Am J Physiol. 255:1988;R1064-R1068.
6. Miller W.L., Redfield M.N., Burnett J.C. Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 83:1989;317-320.
7. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelly R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
8. Tsutamoto T., Wada A., Maeda Y., Adachi T., Kinoshita M. Relation between endothelin-1 spillover in the lungs and the pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 23:1994;1427-1433.
9. Margulies K.B., Hildebrand F.L. Jr., Lerman A., Perrella M.A., Burnett J.C. Jr. Increased endothelin in experimental heart failure. Circulation. 82:1990;2226-2230.
10. Shimoyama H., Sabbah H.N., Borzak S.et al. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation. 94:1996;779-784.
11. Sakai S., Miyauchi T., Kobayashi M.et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
12. Mulder P., Richard V., Derumeaux G.et al. Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 96:1997;1976-1982.
13. Cohn J.N., Johnson G., Ziesche S.et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
14. Wada A., Maeda Y., Matsuda Y., Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptides in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase coupled receptor. Circulation. 89:1994;2232-2240.
15. A receptor antagonist. J Pharmacol Exp Ther. 264:1992;1040-1046.
16. B-mediated blood pressure responses in rats. J Pharmacol Exp Ther. 270:1994;728-733.
17. Hendry B.M., James A.F. Endothelin antagonists in renal disease. Lancet. 350:1997;381-382.
18. Plumpton C., Ferro C.J., Haynes W.G., Webb D.J., Davenport A.P. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol. 119:1996;311-314.
19. B receptor antagonists in congestive heart failure. J Am Coll Cardiol. 30:1997;1385-1392.
20. Wada A., Tsutamoto T., Maeda Y.et al. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol. 270:1995;H1819-H1824.
21. Bayliss J., Norell M.S., Canepa-anson R.et al. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J. 290:1985;1861-1865.
22. B receptors in endothelin-1-induced adrenal catecholamine secretion in vivo. Am J Physiol. 272:1997;R1290-R1297.
23. Takagi Y., Matsuoka H., Atarashi K., Yagi S. Endothelin: a new inhibitor of renin release. Biochem Biophys Res Commun. 157:1988;1164-1168.
24. Cavero P.G., Miller W.L., Heublein D.M., Margulies K.B., Burnett J.C. Jr. Endothelin in experimental congestive heart failure in anaesthetized dog. Am J Physiol. 259:1990;F312-F317.
25. Davis J.O., Freeman R.H. Mechanism regulating renin release. Physiol Rev. 56:1976;1-56.
26. Belloni A.S., Rossi G.P., Andreis P.G.et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 27:1996;1153-1159.
27. Fukuda Y., Hirata Y., Toshimi H.et al. Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun. 155:1988;167-172.
28. Tsutamoto T., Wada A., Maeda K.et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 96:1997;509-516.
29. Karet F., Davenport A. The endothelin system in the kidney. Nephrology. 2:1996;73-85.
30. 2 accumulation in rat IMCD. Am J Physiol. 265:1993;F670-F676.
31. Clavell A.L., Stingo A.J., Margulies K.B., Brandt R.R., Burnett J.C. Jr. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol. 268:1995;F455-F460.
32. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS) N Engl J Med 1987;316:1429-1435.
33. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
34. Bayliss J., Norell M., Canepa-Anson R., Poole-Wilson P.A., Sutton G.C. Renal vascular response to neuroendocrine vasodilatation in chronic heart failure. Br Heart J. 53:1984;107.